This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Products from multiple soldto's are in cart. Only products from single soldto is allowed in cart.
No Items In Cart
As the adoption and acceptance of self-administered therapies grows, patients are spending less time with physicians and are playing a greater role in the delivery and management of their treatments. With the growing demand for extended-release and high-concentration formulations, more drug delivery systems choices are now available to differentiate drug products in a crowded market. Patient preferences can drive the selection of self-injection systems for a drug therapy. Selecting a system that patients prefer can, simplify use and increase compliance with the dosage regimen.
An auto-injector is a drug delivery system designed to deliver a single dose of a drug typically ≤1mL fill volume. Most auto-injectors perform like spring-loaded syringes. By design, auto-injectors are easy to use and are intended for self-administration by patients, or administration by untrained personnel. Auto-injectors were initially designed to overcome the hesitation associated with self-administration of the pre-filled syringe. With a spring loaded auto-injector, the patient does not have control over the injection rate, which at times can cause increased injection site pain during administration. An example of this issue reported from one patient is provided below.
“I tried auto-injectors and the pain was INTENSE to say the very least. It was already painful enough from the pre-filled syringe but the auto-injector does the whole injection in just 15 seconds and for me, that much medicine going into my subcutaneous fat is uncomfortable just from the sheer volume of it, let alone the horrible sting.”
A new injector technology option, the SelfDose® self-injector system provides an integrated drug delivery solution that is manually controlled to minimize discomfort. Furthermore, the integrated safety system helps mitigate the risk of accidental needlestick injuries.
West and one of its pharmaceutical partners conducted multiple human factors studies that reported very favorable results with high scores for “ease of administration,” “confidence of a complete injection without pain” and “satisfied with the injector system.” The following are reported statements from patients, healthcare practitioners and caregivers:
What participants liked about the SelfDose system:
The West SelfDose self-injector system is designed for ease of use, with a feature to hide the needle before and after use; allows the patient to control injection rate, which can improve comfort level; and features intuitive design and operation as confirmed by user studies.
West offers a range of self-injection systems. To learn more, visit our website today.
SelfDose™ is a trademark of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions.
West seeks partners for its SelfDose™ injector technology platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.
Take an in-depth look at the science behind containment & delivery ofinjectable medicines in the West Knowledge Center.
<p><span>At West, we are committed to safeguarding the health and safety of the millions of patients who use our products every day. This commitment is anchored in our Core Value of Leadership in Quality, which ensures we never compromise on quality because we know that patients are counting on us.</span></p>
It has been over a year since China Food and Drug Administration (CFDA) announced <em>Matters Concerning Bundling Review and Approval of Pharmaceutical Packaging Materials, Pharmaceutical Excipients and Drugs</em> (Document No.134 ). As a result, the China pharmaceutical packaging industry is experiencing a revolution.
West is honored to be a recipient of the Philadelphia Business Journal’s 2019 Faces of Philanthropy Award. The honor was presented to West at the Business Journal’s Faces of Philanthropy Awards Breakfast on April 11, 2019 in Philadelphia, PA.
I retired from West in 2017. My West experience over my 34 years of being a team member left me with many fond memories and relationships that I still have today. West’s motto of integrity, strong work ethic and philanthropy aligned well for what I was looking for in a company when I joined in 1983.
In March technical experts from both West and SCHOTT joined together to share insight on the current trends and challenges of the injectable drug market. The two companies held technical seminars sharing their knowledge and expertise related to component and container selection, as well as the integration of primary packaging for filling from clinical to scale up. <br />